Muhammad Imran Butt, Khalid Mania Alkhalifah, Muhammad Riazuddin, Saud Mohammed Almuammar, Salman Mohammed Almuammar, Ghayda Abdulkader Alhifthi, Fahad Wali Ahmed, Samia Mohamed Al Hashim, Najeeb Waheed
{"title":"西马鲁肽的有效性和安全性：来自沙特阿拉伯的真实三级护理经验。","authors":"Muhammad Imran Butt, Khalid Mania Alkhalifah, Muhammad Riazuddin, Saud Mohammed Almuammar, Salman Mohammed Almuammar, Ghayda Abdulkader Alhifthi, Fahad Wali Ahmed, Samia Mohamed Al Hashim, Najeeb Waheed","doi":"10.5144/0256-4947.2024.361","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful.</p><p><strong>Objectives: </strong>Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.</p><p><strong>Design: </strong>Retrospective review of medical records.</p><p><strong>Setting: </strong>Department of medicine at our institution.</p><p><strong>Patients and methods: </strong>This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic. The weight, height, body mass index, blood pressure, and laboratory data, including serum creatinine and hemoglobin A1c (HbA1c) levels and urine albumin/creatinine ratio, were recorded. Moreover, any history of medical comorbidities, such as cardiovascular diseases, cerebrovascular diseases, and heart failure, was documented before and after drug administration.</p><p><strong>Main outcome measures: </strong>Glycemic and weight loss efficacy.</p><p><strong>Sample size: </strong>1007 patients.</p><p><strong>Results: </strong>The median age of the patients was 57.0 years, comprising 60.28% females. Among them, 955 and 442 patients received the medication for at least 3 and 6 months, respectively. Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes. Similar results were observed in the patients without diabetes in terms of weight along with a significant decrease in diastolic blood pressure. Our results also show stability in the serum creatinine and urine albumin creatinine ratio. The drug was equally effective in males and females.</p><p><strong>Conclusion: </strong>Treatment with once-weekly subcutaneous semaglutide (1 mg) led to clinically significant weight loss and improved HbA1c level and cardiometabolic risk factors such as blood pressure.</p><p><strong>Limitations: </strong>Retrospective design.</p>","PeriodicalId":93875,"journal":{"name":"Annals of Saudi medicine","volume":"44 6","pages":"361-368"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627033/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.\",\"authors\":\"Muhammad Imran Butt, Khalid Mania Alkhalifah, Muhammad Riazuddin, Saud Mohammed Almuammar, Salman Mohammed Almuammar, Ghayda Abdulkader Alhifthi, Fahad Wali Ahmed, Samia Mohamed Al Hashim, Najeeb Waheed\",\"doi\":\"10.5144/0256-4947.2024.361\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful.</p><p><strong>Objectives: </strong>Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.</p><p><strong>Design: </strong>Retrospective review of medical records.</p><p><strong>Setting: </strong>Department of medicine at our institution.</p><p><strong>Patients and methods: </strong>This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic. The weight, height, body mass index, blood pressure, and laboratory data, including serum creatinine and hemoglobin A1c (HbA1c) levels and urine albumin/creatinine ratio, were recorded. Moreover, any history of medical comorbidities, such as cardiovascular diseases, cerebrovascular diseases, and heart failure, was documented before and after drug administration.</p><p><strong>Main outcome measures: </strong>Glycemic and weight loss efficacy.</p><p><strong>Sample size: </strong>1007 patients.</p><p><strong>Results: </strong>The median age of the patients was 57.0 years, comprising 60.28% females. Among them, 955 and 442 patients received the medication for at least 3 and 6 months, respectively. Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes. Similar results were observed in the patients without diabetes in terms of weight along with a significant decrease in diastolic blood pressure. Our results also show stability in the serum creatinine and urine albumin creatinine ratio. The drug was equally effective in males and females.</p><p><strong>Conclusion: </strong>Treatment with once-weekly subcutaneous semaglutide (1 mg) led to clinically significant weight loss and improved HbA1c level and cardiometabolic risk factors such as blood pressure.</p><p><strong>Limitations: </strong>Retrospective design.</p>\",\"PeriodicalId\":93875,\"journal\":{\"name\":\"Annals of Saudi medicine\",\"volume\":\"44 6\",\"pages\":\"361-368\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627033/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Saudi medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5144/0256-4947.2024.361\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5144/0256-4947.2024.361","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.
Background: Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful.
Objectives: Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.
Design: Retrospective review of medical records.
Setting: Department of medicine at our institution.
Patients and methods: This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic. The weight, height, body mass index, blood pressure, and laboratory data, including serum creatinine and hemoglobin A1c (HbA1c) levels and urine albumin/creatinine ratio, were recorded. Moreover, any history of medical comorbidities, such as cardiovascular diseases, cerebrovascular diseases, and heart failure, was documented before and after drug administration.
Main outcome measures: Glycemic and weight loss efficacy.
Sample size: 1007 patients.
Results: The median age of the patients was 57.0 years, comprising 60.28% females. Among them, 955 and 442 patients received the medication for at least 3 and 6 months, respectively. Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes. Similar results were observed in the patients without diabetes in terms of weight along with a significant decrease in diastolic blood pressure. Our results also show stability in the serum creatinine and urine albumin creatinine ratio. The drug was equally effective in males and females.
Conclusion: Treatment with once-weekly subcutaneous semaglutide (1 mg) led to clinically significant weight loss and improved HbA1c level and cardiometabolic risk factors such as blood pressure.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
